- Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung - ...
- Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) has been reported under FDA Emergency Use IND authorization at multiple clinical sites GENEVA, Switzerland ...
GENEVA & RADNOR, Pa.-- (BUSINESS WIRE)--RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that the phase 2/3 clinical trial evaluating RLF-100 as a ...
RADNOR, Pa. and GENEVA, Dec. 7, 2020 /PRNewswire/ -- NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCQB: RLFTF) ("Relief") today announced that they have met the 165 patient enrollment ...
RLF-100 ® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids, which was first discovered in 1970. Although initially identified in the intestinal ...
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 17-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...
Early in the Covid-19 pandemic, a research and development (R&D) consultant at Swiss pharma company Relief Therapeutics, Yves Sagot, realised that a drug developed in the early 2000s for acute ...
Type: A synthetic human vasoactive intestinal polypeptide (VIP). VIP is known to reduce inflammation in the lungs by inhibiting inflammatory cytokines and protecting the alveolar type II cells that ...
RADNOR, Pa. & GENEVA--(BUSINESS WIRE)--NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) “Relief” today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory ...
ZURICH (Reuters) - The U.S. Food and Drug Administration has granted NeuroRx Inc Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and ...
TEL AVIV (Reuters) - Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United ...
GENEVA (April 17, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to delivering innovative treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback